What is the address of Mathis Pharma?

The registered office of Mathis Pharma is located at Astridlaan 374a, 8310 Brugge.

Is Mathis Pharma still active?

Yes. According to the CBE (3 October 2026) Mathis Pharma is active, legal situation “Normale toestand”, started on 19 July 2006.

Is Mathis Pharma registered on Peppol?

Yes, Mathis Pharma is registered on the Peppol network with ID 0208:0882624180.

What is the enterprise number of Mathis Pharma?

The enterprise number of Mathis Pharma is BE0882624180.

When was Mathis Pharma founded?

Mathis Pharma was founded on 19 July 2006.

Who are the directors of Mathis Pharma?

According to the 2025 annual accounts, the directors of Mathis Pharma are: Isabelle Deschilder.

Is Mathis Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 19 July 2006; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Mathis Pharma make in 2025?

Mathis Pharma posted a profit after taxes of € 72,397 in financial year 2025.

What is the revenue of Mathis Pharma?

As a small company, Mathis Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 94,444.

Mathis Pharma (Private Limited) - Brugge - BE0882624180

Q: What does Mathis Pharma do?

Mathis Pharma is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 19 July 2006, 1 establishment.

Dossier Mathis Pharma, printed on 3 October 2026 from databakkes.be/en/0882624180/mathis-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 27 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Mathis Pharma from Brugge, company number BE0882624180, closed financial year 2025 with a result of € 72,397 after tax. For that financial year Mathis Pharma recorded a gross margin of € 94,444 and equity of € 557,228. Compared with financial year 2024, the result moved from € 130,225 to € 72,397. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 30, 2026.

What it is worth Growing

€ 557,228

▲ 8% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 72,397

▼ 44% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 39,049

▼ 9% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 30,833 paid out

43 % of the profit went to the shareholders, the rest stayed in the company.

Debts at end 2025

Bank debt ≈ 5 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 218,744

▼ 16% vs 2024

€ 42,146 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.

Owed to suppliers

€ 8,889

▲ 4% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 24,375

▼ 1% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 99,870 Gross margin 2022: € 99,870 First fiscal year in the series	€ 84,014 Gross margin 2023: € 84,014 ▼ 16% vs 2022 (€ 99,870) Unfavourable step	€ 128,434 Gross margin 2024: € 128,434 ▲ 53% vs 2023 (€ 84,014) Favourable step	€ 94,444 Gross margin 2025: € 94,444 ▼ 26% vs 2024 (€ 128,434) Unfavourable step	▼ 26%
Profit after taxes	€ 54,039 Profit after taxes 2022: € 54,039 First fiscal year in the series	€ 41,979 Profit after taxes 2023: € 41,979 ▼ 22% vs 2022 (€ 54,039) Unfavourable step	€ 130,225 Profit after taxes 2024: € 130,225 ▲ 210% vs 2023 (€ 41,979) Favourable step	€ 72,397 Profit after taxes 2025: € 72,397 ▼ 44% vs 2024 (€ 130,225) Unfavourable step	▼ 44%
Equity	€ 366,393 Equity 2022: € 366,393 First fiscal year in the series	€ 413,772 Equity 2023: € 413,772 ▲ 13% vs 2022 (€ 366,393) Favourable step	€ 515,664 Equity 2024: € 515,664 ▲ 25% vs 2023 (€ 413,772) Favourable step	€ 557,228 Equity 2025: € 557,228 ▲ 8% vs 2024 (€ 515,664) Favourable step	▲ 8%
Total debts	€ 591,448 Total debts 2022: € 591,448 First fiscal year in the series	€ 532,445 Total debts 2023: € 532,445 ▼ 10% vs 2022 (€ 591,448) Favourable step	€ 518,507 Total debts 2024: € 518,507 ▼ 3% vs 2023 (€ 532,445) Favourable step	€ 477,827 Total debts 2025: € 477,827 ▼ 8% vs 2024 (€ 518,507) Favourable step	▼ 8%
Cash	€ 11,306 Cash 2022: € 11,306 First fiscal year in the series	€ 15,057 Cash 2023: € 15,057 ▲ 33% vs 2022 (€ 11,306) Favourable step	€ 43,030 Cash 2024: € 43,030 ▲ 186% vs 2023 (€ 15,057) Favourable step	€ 39,049 Cash 2025: € 39,049 ▼ 9% vs 2024 (€ 43,030) Unfavourable step	▼ 9%
Retained profit	€ 353,993 Retained profit 2022: € 353,993 First fiscal year in the series	€ 395,172 Retained profit 2023: € 395,172 ▲ 12% vs 2022 (€ 353,993) Favourable step	€ 497,064 Retained profit 2024: € 497,064 ▲ 26% vs 2023 (€ 395,172) Favourable step	€ 538,628 Retained profit 2025: € 538,628 ▲ 8% vs 2024 (€ 497,064) Favourable step	▲ 8%
Dividend	€ 800 Dividend 2022: € 800 First fiscal year in the series	€ 800 Dividend 2023: € 800 Unchanged (€ 800) Unchanged	€ 28,333 Dividend 2024: € 28,333 ▲ € 27,533 vs 2023 (€ 800) Unchanged	€ 30,833 Dividend 2025: € 30,833 ▲ 9% vs 2024 (€ 28,333) Unchanged	▲ 9%
Bank debt	€ 380,964 Bank debt 2022: € 380,964 First fiscal year in the series	€ 330,715 Bank debt 2023: € 330,715 ▼ 13% vs 2022 (€ 380,964) Favourable step	€ 260,118 Bank debt 2024: € 260,118 ▼ 21% vs 2023 (€ 330,715) Favourable step	€ 218,744 Bank debt 2025: € 218,744 ▼ 16% vs 2024 (€ 260,118) Favourable step	▼ 16%
Balance sheet total	€ 977,841 Balance sheet total 2022: € 977,841 First fiscal year in the series	€ 966,217 Balance sheet total 2023: € 966,217 ▼ 1% vs 2022 (€ 977,841) Unchanged	€ 1,054,170 Balance sheet total 2024: € 1,054,170 ▲ 9% vs 2023 (€ 966,217) Unchanged	€ 1,055,055 Balance sheet total 2025: € 1,055,055 Unchanged (€ 1,054,170) Unchanged

Key figures of Mathis Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Mathis Pharma?

What happened at Mathis Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 30, 2026 New annual accounts for financial year 2025: profit of € 72,397 (▼ 44% vs 2024). filed late Source: NBB ↗
Jul 19, 2006 New establishment in Brugge. KBO
Jul 19, 2006 Start of the company according to the CBE. KBO

In short

From € 54,039 profit in 2022 to € 72,397 profit in 2025.

Paid € 96,445 in corporate taxes since 2022.

Best year ever: 2024, with € 130,225 profit.

Paid out € 60,766 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Mathis Pharma? We notify you, reason included.

Follow Mathis Pharma

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Isabelle Deschilder

Mathis Pharma

Apotheek Deschilder 99%

Behind Mathis Pharma is Isabelle Deschilder. It owns 99% of Apotheek Deschilder itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Isabelle Deschilder

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Astridlaan 374a

8310 Brugge

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0882.624.180

VAT number

BE 0882.624.180

Registered office

Astridlaan 374a, 8310 Brugge

Names & denominations

Mathis Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

19 July 2006

Peppol

Active · Active since 3 Feb 2025

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Activiteiten van holdings

Detailhandel in farmaceutische producten

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

Mathis Pharma

Warning lights

Financials

What happened to Mathis Pharma?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions